EUVIMEDEUVIMED entdecken
Crossref

Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission

Brian H Kushner iD, Charlie White, Audrey Mauguen, Fiorella Iglesias Cardenas, Ellen M Basu, Wei Wei, Kim Kramer, Shakeel Modak iD

International Journal of Cancer · 2026

DOI: 10.1002/ijc.70329 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Brian H Kushner und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Glycolipids, Granulocyte-Macrophage Colony-Stimulating Factor, Cancer Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Katie's Find A Cure Fund, Rhyan Loos Family Fund, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Naxitamab + GM‐CSF was effective against chemo‐resistant high‐risk neuroblastoma (HR‐NB), leading to approval by the Food and Drug Administration. We now describe toxicity and outcome of patients treated in first complete remission (CR) with naxitamab plus novel dosing of GM‐CSF (nGM‐CSF), initiated in February 2021, based on pharmacologic data. Treatment also included an anti‐NB vaccine but no prior myeloablative therapy (MAT). This retrospective study covers all first CR HR‐NB patients who started the novel naxitamab + nGM‐CSF regimen from February 22, 2021 to December 11, 2023. As before, naxitamab (3 mg/kg) was infused on days 1–3–5 (i.e., 3 doses/cycle). Previously, priming doses of GM‐CSF 250 μg/m 2 /day were subcutaneously administered ×5 (days −4 to 0), followed by step‐up to 500 μg/m 2 /day ×5 (days 1 to 5), but now priming doses were ×3 (days −2 to 0) and stepped‐up dosing was ×7 (days 1 to 7), that is, through 2 days after the last dose of naxitamab. After completing antibody treatment (5 monthly cycles), patients could receive vaccine. Event‐free survival (EFS) and overall survival (OS) were calculated from start of naxitamab + nGM‐CSF. Forty‐three patients received 157 cycles. Acute toxicities were generally manageable, allowing outpatient treatment. Stepped‐up dosing and extended administration of GM‐CSF had no associated toxicity, hematological or otherwise. Human anti‐human antibody developed in 5/43 (12%) patients. Thirty‐four (79%) patients received the vaccine; 9 did not due to relapse ( n = 4) and parental choice ( n = 5). EFS/OS rates at 24 months were 88%/95% and at 36 months were 80%/95%. Naxitamab + nGM‐CSF is a good option to consolidate first CR of HR‐NB patients, including those who did not undergo MAT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGlycolipidsGranulocyte-Macrophage Colony-Stimulating FactorCancer VaccinesNeuroblastomaAntineoplastic Combined Chemotherapy ProtocolsRetrospective StudiesDrug Administration ScheduleDose-Response Relationship, DrugInfusions, IntravenousInjections, SubcutaneousProgression-Free SurvivalHumansMaleFemaleInfantChild, PreschoolChildAdolescent

Stichwörter der Autor:innen

GM‐CSFanti‐GD2 antibodyimmunotherapynaxitamabneuroblastomavaccine

Substanzen

naxitamabAntibodies, Monoclonal, HumanizedGlycolipidsGranulocyte-Macrophage Colony-Stimulating FactorCancer Vaccines

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Brian H Kushner, Shakeel Modak

Förderung

  • Katie's Find A Cure Fund
  • Rhyan Loos Family Fund
  • NCI NIH HHS
  • Band of Parents Foundation
  • Robert Steel Foundation
  • National Cancer Institute
  • Robert K Steel Family Foundation

Zitieren

APA

Kushner, B. H., White, C., Mauguen, A., Cardenas, F. I., Basu, E. M., Wei, W., Kramer, K., & Modak, S. (2026). Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission. International Journal of Cancer. https://doi.org/10.1002/ijc.70329

Vancouver

Kushner BH, White C, Mauguen A, Cardenas FI, Basu EM, Wei W, et al. Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission. International Journal of Cancer. 2026. doi:10.1002/ijc.70329

BibTeX
@article{Kushner2026,
  author = {Kushner, Brian H and White, Charlie and Mauguen, Audrey and Cardenas, Fiorella Iglesias and Basu, Ellen M and Wei, Wei and Kramer, Kim and Modak, Shakeel},
  title = {Naxitamab with novel scheduling and stepped‐up dosing of GM ‐ CSF plus vaccine, but no myeloablative therapy for patients with high‐risk neuroblastoma in first complete remission},
  journal = {International Journal of Cancer},
  year = {2026},
  doi = {10.1002/ijc.70329}
}
Kostenlos starten →